OmniAb Investor Presentation Deck

Ion Channels and Transporters DIFFERENTIATED ION CHANNELS AND TRANSPORTERS DISCOVERY PLATFORM AT OMNIAB ● ● One of industry's most experienced teams of ion channel discovery experts Continuous expansion and development of cutting-edge technologies including high-throughput electrophysiology and compound screening assays, structure- based optimization leveraging cryo-EM and molecular dynamics, deep learning models, proprietary X-ray fluorescence, etc. Extensive bank of custom cell lines, reagents and assays designed to accelerate ion channel drug discovery and development K2P Kv K2P K₂3 Kv10-11 K,10 K₂9 K₂11 K,12 Kako? KCa CNGB CNGA Ka 1.5 Ca2 Ca¹ ca.3 K6 K₂2 Cav Kir Nav Nav TRPM TRPP TRPML TRPC ANKTM1 TRPV TRP Single Cell Line(s) Compound Screening Assays Figure does not reflect all ion channel or transporter families, disease variants, species orthologs or bespoke constructs generated to accelerate therapeutic candidate selection that are available at OmniAb, Inc. Collaborations for High-Value Targets GSK 2 Programs (both discovery stage) Neurological Diseases ● Roche 3 Programs (all discovery stage) 24 Neurodevelopmental & Neurodegenerative Diseases In addition to on-going Collaboration/ Service Revenue, the discovery-stage programs with these two partners have a potential to generate: $1 billion in milestones Royalties on future sales OmniAb

View entire presentation